Evidence map›Paper›PMID 30050623›Full record

ArticleThe Pan African medical journal2018

[Evolution of biochemical and hematological parameters in patients living with HIV/AIDS treated with antiretroviral therapy at the Aboubacar Sangoulé Lamizana General Camp Medical Center].

Raoul Karfo, Elie Kabré, Laetitia Coulibaly, Georges Diatto, Jean Sakandé, Lassana Sangaré

Abstract read
In one paragraph

Article in The Pan African medical journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Raoul KarfoClinique du Laboratoire de Biologie du Centre Médical du Camp Général Aboubacar Sangoulé Lamizana,Ouagadougou, Burkina Faso.
Elie KabréUnité de Formation et de Recherche en Sciences de la Santé, Université de Ouagadougou,Ouagadougou, Burkina Faso.
Laetitia CoulibalyUniversité Saint Thomas d'Aquin (USTA),Ouagadougou, Burkina Faso.
Georges DiattoClinique de Dermatologie du Centre Médical du Camp Général Aboubacar Sangoule Lamizana, Ouagadougou, Burkina Faso.
Jean SakandéUnité de Formation et de Recherche en Sciences de la Santé, Université de Ouagadougou,Ouagadougou, Burkina Faso.
Lassana SangaréClinique du Laboratoire de Biologie du Centre Médical du Camp Général Aboubacar Sangoulé Lamizana,Ouagadougou, Burkina Faso.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study aimed to evaluate the impact of treatment on biochemical and hematological parameters in HIV-positive patients followed up at the Aboubacar Sangoulé Lamizana General Camp Medical Center in Burkina Faso.

methodsWe conducted a retrospective study over the period January 2010-September 2015. The study only included HIV-positive patients treated with ART having undergone laboratory tests at treatment initiation (M0), at sixth month (M6), and at twelfth month (M12).

resultsSex-ratio was 0.88 and the most affected age group was 45-55 years. The most prescribed treatments were triple combination therapies based on 2INTI + 1INNTI (74,5%), 2INTI+1 IP (14,9%). Viral load test was little requested. The rate of patients with normal laboratory tests showed a statistically significant regression between M0 (70%), and M6 (13%) (p<0.05). Severely immunocompromised patients showed a significant increase in average TCD4 lymphocytes value, ranging from 79,22 at M0 to 227.95 cells/mm

conclusionThe increase in the rate of TCD4 lymphocytes and in the rate of hemoglobin levels gives an indication of ART effectiveness and of patient's tolerance to treatment. Viral load test accessibility and an improvement in laboratory testing monitoring are essential.

Indexed as

CD4 Lymphocyte CountAcquired Immunodeficiency SyndromeAdolescentAdultAnti-HIV AgentsBurkina FasoFemaleFollow-Up StudiesHemoglobinsHIV InfectionsHumansImmunocompromised HostMaleMiddle AgedRetrospective StudiesTreatment OutcomeAnti-HIV AgentsHemoglobinsAntiretroviral therapybiological monitoringHIV/AIDSTCD4 lymphocytes

Identifiers

PMID30050623
PMCPMC6057560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.